• Brazilin, Ferroptosis, and the p53/SLC7A11/GPX4 Axis

  2026-10-05

  A 2024 study reports that brazilin suppresses 4T1 breast cancer cell growth while producing biochemical, mitochondrial, and protein-expression changes consistent with ferroptosis. Its central contribution is the proposed connection between brazilin activity and the p53/SLC7A11/GPX4 pathway, although the single-cell-line, in vitro design limits causal and translational conclusions.

• Recombinant Human EGF in Cancer Stemness Research

  2026-10-05

  Epidermal Growth Factor is a biologically plausible signaling input for studying proliferation, differentiation, and glioblastoma cell-state behavior, but current supplied evidence does not directly show that recombinant human EGF drives the spheroid findings reported by Chen et al. This overview separates supplier-reported product characteristics from published assay findings and defines the limits of interpreting spheroid formation as a stemness measure.

• Ferrostatin-1 in Ferroptosis Research: Evidence Overview

  2026-10-04

  Ferrostatin-1 (Fer-1) is a research compound used to investigate ferroptosis, an iron-dependent form of regulated cell death involving oxidative damage to membrane lipids. This overview places Fer-1 in context, examines its reported relevance to cancer biology research and ferroptosis assays, and evaluates findings from a 2022 epithelial ovarian cancer study involving the ADAMTS9-AS1–miR-587–SLC7A11 axis. The available evidence supports mechanistic use as a pharmacological probe, but does not establish clinical efficacy or prove that Fer-1 directly regulates this molecular pathway.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-10-03

  Oliveira and colleagues reported that selected naturally occurring angiotensin peptides increase the apparent binding of SARS-CoV-2 spike protein to host receptors, with the strongest effects associated with shorter or structurally modified peptides. The work provides a biochemical structure–activity framework, while its implications for viral entry, COVID-19 pathogenesis, and treatment remain investigational.

• Dextrose in Hypoxia-Driven Immunometabolism

  2026-10-02

  Learn how Dextrose (D-glucose) enables controlled tumor–immune nutrient-competition models under hypoxia. This practical guide combines stock preparation, oxygen-controlled workflows, assay design, and troubleshooting for reproducible glucose metabolism research.

• Vidarabine Monohydrate: Assay Design Guide

  2026-10-01

  Vidarabine monohydrate is an adenosine-mimetic antiviral research compound for investigating viral DNA synthesis and replication. This guide combines molecular mechanism, solvent planning, assay controls, and a translationally cautious lesson from a recent interaction-screening study.

• 2-Hydroxypropyl-β-cyclodextrin Protocol

  2026-10-01

  2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and formulate poorly water-soluble hydrophobic compounds, especially aromatic or phenyl-containing molecules, through inclusion complex formation. This guide covers dossier values and a practical solubility workflow; it should be treated as a research excipient rather than evidence of therapeutic efficacy or clinical bioavailability.

• Firefly Luciferase mRNA: A Translation Control

  2026-09-30

  Firefly Luciferase mRNA (ARCA, 5-moUTP) can function as more than a bright reporter: it provides a practical bridge between controlled translation studies and reproducible cellular assays. This guide explains how cap chemistry, 5-methoxyuridine, poly(A) design, and experimental context shape the signal.

• Trichostatin A (TSA): Practical HDAC Workflows

  2026-09-30

  Trichostatin A (TSA) converts HDAC biology into measurable assays for chromatin acetylation, cancer-cell phenotypes, and regeneration research. This practical guide connects dose planning, temporal sampling, and troubleshooting with findings from axolotl limb regeneration and breast cancer models.

• Vidarabine Monohydrate: From Mechanism to Translation

  2026-09-29

  A thought-leadership guide to using Vidarabine monohydrate as a mechanistically grounded antiviral research compound, with practical advice on assay design, translational rigor, solubility, and the responsible use of cross-domain screening insights.

• LTI6426 Enhances Panobinostat in Multiple Myeloma

  2026-09-29

  The reference study shows that the orally bioavailable PDI inhibitor LTI6426 can substantially improve low-dose panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. Its main mechanistic contribution is the identification of ATF3, DDIT3/CHOP, and DNAJB1 as coordinated endoplasmic-reticulum-stress response markers that may guide pharmacodynamic studies.

• Morin C5297: Mechanism, Evidence, and Workflows

  2026-09-28

  Morin is a natural flavonoid identified as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. Its reported research uses include oxidative-stress, inflammation, adenosine 5′-monophosphate deaminase, mitochondrial, fluorescence, diabetes, cancer, and neurodegeneration studies, but product bioactivity data do not establish clinical efficacy.

• Bortezomib (PS-341) in Proteasome Assays

  2026-09-28

  Use Bortezomib (PS-341) to test whether proteasomal degradation links protein ubiquitination to cell-state changes—then pair target-protein measurements with viability and apoptosis readouts. A practical workflow connects the MAPK10–KRT16 findings in NSCLC to carefully controlled inhibitor experiments without treating the paper as evidence that it tested bortezomib.

• Temozolomide Assays: Separating Damage From Response

  2026-09-27

  Temozolomide is a small-molecule alkylating agent whose effects depend on both DNA lesions and the cell’s capacity to process them. This article explains how to distinguish direct drug response from combination effects in glioma experiments, with practical guidance for interpreting ATRX-related findings without overcalling synergy.

• Dextrose for Tumor Immunometabolism Research

  2026-09-26

  Use Dextrose (D-glucose) to set a defined nutrient input in tumor-cell and immune-cell experiments—not as a stand-in for hypoxia itself. This practical guide connects glucose-controlled culture design with the tumor-microenvironment framework in a recent review, then covers preparation, assay comparisons, and common troubleshooting decisions.

8122 records 1/542 page Next 12345 下5页 Last page